Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 280 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Testosterone Therapy Clear all

Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Interventions: Olaparib, LHRH agonist; Drug
Lead sponsor: Rana McKay, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: La Jolla, California • Baltimore, Maryland • New York, New York + 2 more

Conditions: Systemic Lupus Erythematosus
Interventions: Prasterone (GL701); Drug
Lead sponsor: Genelabs Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Rancho Mirage, California + 18 more

Conditions: Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Interventions: androgel, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 31 Years to 60 Years · Male only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions: PRL-02 injection, prednisone, dexamethasone, enzalutamide; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more

Conditions: Hypogonadism
Interventions: QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C; Drug
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Breast Cancer
Interventions: DHEA, Surgical resection; Drug · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions: continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp; Device · Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
Interventions: Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer; Drug · Combination Product
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Biospecimen Collection, Prasterone, Survey Administration; Procedure · Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypogonadism, Erectile Dysfunction
Interventions: Testim®, Placebo Testim®, Viagra®; Drug · Other
Lead sponsor: Mohit Khera; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obese Hypogonadotropic Hypogonadism
Interventions: Investigational new drug company code: BGS649, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Tucson, Arizona • San Diego, California • Miramar, Florida + 1 more

Conditions: Long QT Syndrome, Abnormalities, Drug-Induced
Interventions: Progesterone, Ibutilide, Testosterone, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 50 Years to 99 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Hypogonadism
Interventions: Testosterone MD-Lotion; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Tuscon, Arizona • Burbank, California • New Britain, Connecticut + 1 more

Conditions: Sexual Dysfunction, Physiological
Interventions: Testosterone Cream, Estring; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Secondary Hypogonadism
Interventions: Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 8
States / cities: Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more

Conditions: Type 2 Diabetes, Hypogonadism
Interventions: Androgel (testosterone gel); Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 70
States / cities: Birmingham, Alabama • Calera, Alabama • Mobile, Alabama + 54 more

Conditions: Hypogonadism, Male
Interventions: Testosterone Cypionate Injection 200 mg/mL; Drug
Lead sponsor: Azurity Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 3 more

Conditions: Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications, Sexual Dysfunction
Interventions: testosterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 528
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 331 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 3 more

Conditions: Hypogonadism, Aging, Overweight and Obesity
Interventions: Testosterone replacement, lifestyle; Drug · Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 65 Years to 85 Years · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Muscle Atrophy, Surgery, Knee Injuries and Disorders, Complication of Surgical Procedure, Trauma
Interventions: Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection; Drug · Other
Lead sponsor: The Stone Research Foundation for Sports Medicine and Arthritis; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: clarithromycin, prasterone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Infertility, Female, Obesity
Interventions: Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone; Other · Dietary Supplement · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Low Testosterone
Interventions: TAK-448, TAK-448 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 60 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Pharmacokinetic Study of Testosterone Enanthate

DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Testosterone for Penile Rehabilitation After Radical Prostatectomy

Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes

Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men

Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

Use of a Test That Evaluates How the Body Handles Insulin and Glucose

Long-term Lifestyle Change and Testosterone Replacement

Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

Mediators of Abnormal Reproductive Function in Obesity (MARO)

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone